James Harrison


James Harrison was formerly CEO of Archimica, an international contract manufacturing organisation of active pharmaceutical ingredients and their pre-cursors for the global branded and generic pharmaceutical industries.

Archimica has manufacturing sites in the US, UK, Germany, France and Italy.  During his tenure at Archimica, James recruited and led a new management team, and implemented a detailed strategic repositioning of the business. Archimica was sold to the Euticals group in 2011.

Prior to Archimica, James was a Managing Director at TowerBrook Capital Partners and a Partner at Soros Private Equity Partners. James began his career working in the mergers and acquisitions department of Morgan Stanley.

Bill Robinson


Mr Robinson was formerly COO of UCB, a Brussels-based global biopharmaceutical company, where as a member of the Executive Committee, he was responsible for their global commercial operations.  Previously, Mr Robinson had worked for over 35 years for Eli Lilly, one of the leading US pharmaceutical companies, where he held a number of senior international management roles in Sales and Marketing, General Management, and Research and Development. Prior to his retiring from Lilly he was VP for US Sales and Marketing.

Bill is a former Chairman of Plethora Solutions an AIM-listed UK pharmaceutical company, and a former Board Director of Sciele Pharma, which was a NASDAQ listed company prior to its acquisition by Shionogi.

Duncan Moore


Dr Moore was previously the Global Head of Healthcare Research at Morgan Stanley.

He is Chairman of Lamellar Biomedical, Chairman of Oncology Venture and Chairman of StepJockey. Dr Moore is also a Board Director of Forward Pharma, the NASDAQ listed biotechnology company and he is a partner in East West Capital Partners.

Ross Reason


Mr Reason, a fellow of Robinson College, University of Cambridge is an economist, accountant and former head of trading at an investment bank.

Mr Reason is currently on the board of a number of companies including Cambridge University Investment Management Ltd, HgCapital LLP and ED&F Man, amongst others.

David Buckeridge


Dr. Buckeridge has 35 years of operational management experience in the life science and agribusiness industries. After serving as Group CEO of Advanta BV, the largest independent agronomic seed business in the world at that time, David led its highly successful exit from private equity ownership to a strategic Asian buyer and then advised on preparation for its successful IPO to the Indian stock market in 2007. Subsequently, he has played a senior advisory role to both strategic and financial investors in his core sectors, focusing on the operational and strategic planning aspects of these industries.
He began his career with the multinational pharmaceutical company AstraZeneca, spending approximately 20 years in a variety of management positions globally.

He has served as director and Chairman of a range of companies in the agribusiness, pharma, and public health industries. Currently, Dr. Buckeridge serves on the Boards of ScanBio Marine Group, Spearhead International, Rivulis, and Verdesian Life Sciences. He is also an independent director of Velcourt Ltd, the UK’s largest farm management company.
He has a Bachelor of Science and Ph.D. in Genetics and Plant Sciences from the University of Wales (U.K.)

Alejandra Bruna


Dr Alejandra Bruna is a cancer biologist who leads the Preclinical Modelling of Paediatric Cancer Evolution team at the Institute of Cancer Research, London. Dr Bruna leads and contributes to preclinical programmes using improved patient-derived tumour models building towards an integrative and personalised approach to cancer medicine.

Dr Bruna obtained her Ph.D. from the University of Barcelona, followed by two postdoctoral fellowships at Mount Sinai School of Medicine, New York City and Vall d’Hebron Institute, Barcelona.

Dr Bruna coordinated and co-led one of the largest translational research efforts in the academia setting by developing and validating a framework for deep molecular and phenotypically annotated patient-derived tumour xenografts (PDXs) and short-term cultures of PDX cells with Professor Carlos Caldas at the Cancer Research UK Cambridge Institute. Dr Bruna is now expanding her experience and expertise into paediatric cancers by leading a team at the ICR to help achieve kinder and smarter treatments for children with cancer.